Every week the Editor-in-Chief selects the Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.
In addition to the article itself, there is an accompanying blog written by a prominent member of the urological community. This blog is intended to provoke comment and discussion and we invite you to use the comment tools at the bottom of each post to join the conversation.
Finally, the third post under the Article of the Week heading on the homepage will consist of additional material or media. This week we feature a video of Michael Conlin discussing his paper.
If you only have time to read one article this week, it should be this one.
A single dose of a non-steroidal anti-inflammatory drug (NSAID) prevents severe pain after ureteric stent removal: a prospective, randomised, double-blind, placebo-controlled trial
Nicholas N. Tadros, Lisa Bland, Edith Legg, Ali Olyaei and Michael J. Conlin
• To determine the incidence of severe pain after ureteric stent removal.
• To evaluate the eﬃcacy of a single dose of a non-steroidal anti-inﬂammatory drug (NSAID) in preventing this complication.
PATIENTS AND METHODS
• A prospective, randomised, double-blind, placebo-controlled trial was performed at our institution.
• Adults with an indwelling ureteric stent after ureteroscopy were randomised to receive either a single dose of placebo or an NSAID (rofecoxib 50 mg) before ureteric stent removal.
• Pain was measured using a visual analogue scale (VAS) just before and 24 h after stent removal.
• Pain medication use after ureteric stent removal was measured using morphine equivalents.
• In all, 22 patients were enrolled and randomised into the study before ending the study after interim analysis showed signiﬁcant decrease in pain level in the NSAID group.
• The most common indication for ureteroscopy was urolithiasis (14 patients).
• The proportion of patients with severe pain (VAS score of 7) during the 24 h after ureteric stent removal was six of 11 (55%) in the placebo group and it was zero of 10 in the NSAID group (P < 0.01).
• There were no complications related to the use of rofecoxib.
• We found a 55% incidence of severe pain after ureteric stent removal.
• A single dose of a NSAID before stent removal prevents severe pain after ureteric stent removal.